Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the α7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia:: Synthesis and structure-activity relationship

被引:178
作者
Wishka, Donn G. [1 ]
Walker, Daniel P. [1 ]
Yates, Karen M. [1 ]
Reitz, Steven C. [1 ]
Jia, Shaojuan [1 ]
Myers, Jason K. [1 ]
Olson, Kirk L. [1 ]
Jacobsen, E. Jon [1 ]
Wolfe, Mark L. [1 ]
Groppi, Vincent E. [1 ]
Hanchar, Alexander J. [1 ]
Thornburgh, Bruce A. [1 ]
Cortes-Burgos, Luz A. [1 ]
Wong, Erik H. F. [1 ]
Staton, Brian A. [1 ]
Raub, Thomas J. [1 ]
Higdon, Nicole R. [1 ]
Wall, Theron M. [1 ]
Hurst, Raymond S. [1 ]
Walters, Rodney R. [1 ]
Hoffmann, William E. [1 ]
Hajos, Mihaly [1 ]
Franklin, Stanley [1 ]
Carey, Galen [1 ]
Gold, Lisa H. [1 ]
Cook, Karen K. [1 ]
Sands, Steven B. [1 ]
Zhao, Sabrina X. [1 ]
Soglia, John R. [1 ]
Kalgutkar, Amit S. [1 ]
Arneric, Stephen P. [1 ]
Rogers, Bruce N. [1 ]
机构
[1] Pfizer Global Res & Dev, Groton, CT 06340 USA
关键词
D O I
10.1021/jm0602413
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
N-[(3R)-1-Azabicyclo[2.2.2] oct-3-yl] furo[2,3-c]pyridine-5-carboxamide (14, PHA-543,613), a novel agonist of the alpha 7 neuronal nicotinic acetylcholine receptor (alpha 7 nAChR), has been identified as a potential treatment of cognitive deficits in schizophrenia. Compound 14 is a potent and selective alpha 7 nAChR agonist with an excellent in vitro profile. The compound is characterized by rapid brain penetration and high oral bioavailability in rat and demonstrates in vivo efficacy in auditory sensory gating and, in an in vivo model to assess cognitive performance, novel object recognition.
引用
收藏
页码:4425 / 4436
页数:12
相关论文
共 65 条
[1]  
ADLER LE, 1993, AM J PSYCHIAT, V150, P1856
[2]   ELECTROPHILIC AROMATIC-SUBSTITUTION .33. PARTIAL RATE FACTORS FOR PROTIODETRITIATION OF BENZO[B]THIOPHEN - THE RESONANCE-DEPENDENT REACTIVITY OF THE RING POSITIONS [J].
AMIN, HB ;
AWAD, AA ;
ARCHER, WJ ;
TAYLOR, R .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1982, (11) :1489-1492
[3]  
[Anonymous], 2003, [No title captured], Patent No. [WO 2003070732, 2003070732]
[4]   Recent Progress in the Development of Subtype Selective Nicotinic Acetylcholine Receptor Ligands [J].
Astles, P. C. ;
Baker, S. R. ;
Boot, J. R. ;
Broad, L. M. ;
Dell, C. P. ;
Keenan, M. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2002, 1 (04) :337-348
[5]   MASS-SPECTROMETRY IN THE ANALYSIS OF GLUTATHIONE CONJUGATES [J].
BAILLIE, TA ;
DAVIS, MR .
BIOLOGICAL MASS SPECTROMETRY, 1993, 22 (06) :319-325
[6]  
BITON B, 2004, 34 ANN NEUR M SAN DI
[7]   Discovery and structure -: Activity relationship of quinuclidine benzamides as agonists of α7 nicotinic acetylcholine receptors [J].
Bodnar, AL ;
Cortes-Burgos, LA ;
Cook, KK ;
Dinh, DM ;
Groppi, VE ;
Hajos, M ;
Higdon, NR ;
Hoffmann, WE ;
Hurst, RS ;
Myers, JK ;
Rogers, BN ;
Wall, TM ;
Wolfe, ML ;
Wong, E .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (04) :905-908
[8]   Design of Ligands for the nicotinic acetylcholine receptors: The quest for selectivity [J].
Bunnelle, WH ;
Dart, MJ ;
Schrimpf, MR .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2004, 4 (03) :299-334
[9]   1-HYDROXY-7-AZABENZOTRIAZOLE - AN EFFICIENT PEPTIDE COUPLING ADDITIVE [J].
CARPINO, LA .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1993, 115 (10) :4397-4398
[10]  
CLEMENTI F, 2000, HDB EXPT PHARM NEURO